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Proof-of-Concept Gene Editing 
for the Murine Model of Inducible 
Arginase-1 Deficiency
Yuan Yan Sin, Phillipe R. Price, Laurel L. Ballantyne & Colin D. Funk
Arginase-1 deficiency in humans is a rare genetic disorder of metabolism resulting from a loss of 
arginase-1, leading to impaired ureagenesis, hyperargininemia and neurological deficits. Previously, we 
generated a tamoxifen-inducible arginase-1 deficient mouse model harboring a deletion of Arg1 exons 
7 and 8 that leads to similar biochemical defects, along with a wasting phenotype and death within two 
weeks. Here, we report a strategy utilizing the Clustered, Regularly Interspaced, Short Palindromic 
Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system in conjunction with piggyBac technology 
to target and reincorporate exons 7 and 8 at the specific Arg1 locus in attempts to restore the function 
of arginase-1 in induced pluripotent stem cell (iPSC)-derived hepatocyte-like cells (iHLCs) and 
macrophages in vitro. While successful gene targeted repair was achieved, minimal urea cycle function 
was observed in the targeted iHLCs compared to adult hepatocytes likely due to inadequate maturation 
of the cells. On the other hand, iPSC-derived macrophages expressed substantial amounts of “repaired” 
arginase. Our studies provide proof-of-concept for gene-editing at the Arg1 locus and highlight the 
challenges that lie ahead to restore sufficient liver-based urea cycle function in patients with urea cycle 
disorders.
Arginase-1 (ARG1), highly expressed in liver, is the final enzyme of the urea cycle. Inherited deficiency of this 
enzyme results in hyperargininema with progressive neurological and intellectual impairment, growth retarda-
tion and occasional episodes of hyperammonemia. Treatment of arginase-1 deficiency consists of supportive 
measures including pharmacologic agents to remove excess nitrogen and a low-protein diet. No cure is available1, 
2, although liver transplantation restores liver arginase-1 and appears to prevent progression of the neurologi-
cal symptoms3. We and others have previously generated and characterized similar tamoxifen-inducible mouse 
models of arginase-1 deficiency via Cre-mediated excision of Arg1 exons 7 and 8 that lead to mice nearly devoid 
of hepatic Arg1 enzyme activity with a severe wasting phenotype and death approximately two weeks later4–6. 
Strategies to rescue the lethal phenotype in mice including ornithine supplementation, low-protein diet, nitrogen 
scavengers and a transgenic approach were unsuccessful. Gene therapeutic approaches have also been imple-
mented as a means to correct the lethal phenotype of inducible and global Arg1 knockout mouse models using 
adenoviral and adeno-associated viral (AAV) vectors expressing Arg1. However, none have rescued every feature 
of the genetic deficiency7–12.
Induced pluripotent stem cells (iPSCs) have the capability to undergo unlimited self-renewal and differentiate 
into all cell types13–17, thereby holding great potential for stem cell-based therapies for many untreatable diseases, 
including urea cycle disorders. Concurrent with the application of iPSC technology, the emerging Clustered, 
Regularly Interspaced, Short Palindromic Repeats (CRISPR) CRISPR-associated protein 9 (Cas9) genome editing 
technology18–22 has garnered great interest for potential therapeutic applications due to its ease of use, efficacy, 
specificity and versatility. It is composed of a DNA-cutting enzyme Cas9 and a guide RNA (gRNA) containing 
20 nucleotides of identity to a target sequence proximal to a protospacer-adjacent motif (PAM). Cas9 is directed 
to the intended target site by a gRNA to induce double-stranded breaks (DSBs), which are subsequently repaired 
through endogenous DNA repair mechanisms, either by error prone non-homologous end joining (NHEJ) or 
homology-directed repair (HDR) for precise genome alterations in the presence of exogenously introduced 
homologous DNA template.
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Here, we use iPSCs derived from our inducible model in combination with CRISPR/Cas9 and piggyBac trans-
poson23, 24 systems to provide proof-of-concept for biallelic targeted gene repair of multi-exon deletion in vitro in 
the parental cells, iPSC-derived hepatocyte-like cells (iHLCs) and cells differentiated to macrophages.
Results
Generation and characterization of Arg1-deficient (Arg1Δ) iPSCs. An iPSC-based strategy was 
devised to gene edit the murine model of inducible Arg1 deficiency (Figs 1–3). Primary mouse embryo fibroblasts 
(PMEFs) isolated from Arg1-Cre mouse embryos (Fig. 1a) were treated with 4-hydroxy-tamoxifen (4-OHT) in 
vitro for the excision of floxed exons 7 and 8 to inactivate Arg1. DNA from Arg1-Cre mice yield 1.2 kb and 252 bp 
bands, indicative of intact exons 7 and 8. Successful excision of exons 7 and 8 of Arg1 in PMEFs and derived 
cells yields a band of 195 bp characteristic of the Arg1Δ allele (Fig. 1b). Arg1-deficient iPSCs were generated 
using lentiviral transduction of re-programming factors Klf4, Oct4, Sox2 and c-Myc25. Colonies exhibited typical 
embryonic stem cell-like morphology: dome-shaped, refractile densely packed colonies with high nuclear to 
cytoplasmic ratios, prominent nuclei and distinct colony border after transduction. The undifferentiated state 
showed alkaline phosphatase staining (Fig. 1c), along with the ability to form embryoid bodies under appropriate 
culture conditions (Fig. 1d). Moreover, teratoma formation was observed in immune-deficient mice, showing 
differentiation capability in forming derivatives of all three germ layers as depicted in Fig. 1e.
Figure 1. Generation of Arg1-deficient iPSCs from PMEF cultures. (a) Schematic diagram depicting the 
genotype of cell source. The arrows indicate the positions of the primers used for genotyping the resulting 
cells. (b) PCR genotyping to confirm the deletion of exons 7 and 8. Arg1-Cre PMEFs showed bands at 1.2 kb 
and 252 bp (indicative of intact exons 7 and 8), while both Arg1∆ PMEFs and derived iPSCs produced only one 
band at 195 bp. Skin fibroblasts isolated from a tamoxifen-induced Arg1-deficient mouse were used as a positive 
control, while untreated Arg1-Cre PMEFs served as negative control. (c) Alkaline phosphatase as a pluripotent 
marker. (d) Formation of embryoid bodies and (e) teratoma assay to demonstrate trilineage differentiation in 
vitro and in vivo, respectively. Shown are gutlike epithelial tissues, cartilage and neural tissues, depicting the 
formation of endoderm, mesoderm and ectoderm, respectively.
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CRISPR/Cas9-mediated reincorporation of deleted exons via homology-directed repair. An 
optimal gRNA target candidate was chosen based on the highest scoring for on-target and sequence conserva-
tion with minimal potential off-target effects using an in silico prediction tool. This gRNA was designed de novo 
to target intron 6 of the Arg1 locus for the reincorporation of exons 7 and 8 (Fig. 2a). By in silico analysis, we 
found seven hypothetical off-target sites for this gRNA, which all had at least three mismatched bases (Fig. 2b). 
Hsu et al.26 demonstrated that Cas9 showed no measurable cleavage in targets that had greater than two mis-
matches, independent of their location within the genome. Surveyor nuclease cleavage at the mismatches pro-
duced products of 149 bp and 197 bp (Fig. 2c). This heteroduplex assay determined the ability of gRNA-guided 
Cas9 to induce DSBs in a precise and predictable manner, with mutation frequencies up to 12% in mouse iPSCs. 
Sequencing results confirmed cleavage in the target region as evidenced by the presence of NHEJ-induced indels 
(Fig. 2d).
Once measurable cutting efficiency was achieved, we performed HDR by introducing a donor targeting vector 
together with Cas9:gRNA into Arg1-deficient mouse iPSCs via electroporation. The targeting vector consists of 
exons 7 and 8 cDNA fused to an RFP monomeric-encoding segment with piggyBac inverted terminal repeats 
(ITR) flanking a PGK-puro-tk cassette along with two flanking homology arms of the target region to facilitate 
homologous recombination (Fig. 3a). An HDR stimulatory compound, L-755,507 was added to enhance CRISPR/
Cas9-mediated HDR efficiency27. Puromycin-resistant mouse iPSC colonies obtained after electroporation were 
screened for proper targeting by PCR (Fig. 3b) and genotype confirmed by sequencing (data not shown). 5/23 
iPSC clones were identified as targeted with no random integration, 10/23 were targeted correctly only on one 
arm and 8/23 were non-targeted. Two correctly targeted clones (clones #C2 and #C15) were chosen for subse-
quent piggyBac excision experiments. piggyBac transposase electroporation, followed by ganciclovir selection 
Figure 2. CRISPR/Cas9-mediated gene targeting in mouse iPSCs. (a) Schematic diagram showing the site 
of Arg1 gene modification using CRISPR/Cas9. The gRNA was designed to target a 20 nt region in intron 6 
of Arg1. (b) Cas9:gRNA off-target analysis. A table showing the output from CRISPR design tool. The on-site 
target is given at the top, followed by off-target sequences organized in decreasing Cas9-cleavage probability. 
(c) Detection of Cas9:gRNA-mediated on-target cleavage of Arg1 by the Surveyor nuclease assay. The cleavage 
products were shown as extra bands (149 bp + 197 bp) indicated by the arrows. Mutation frequency (indel) 
was calculated by measuring the band intensities. (d) Sequencing data from TOPO-cloned PCR amplicons 
of CRISPR/Cas9-modified genomic DNA showing a few examples of NHEJ-mediated indel mutations at the 
desired location. gRNA target site is in bold. Deletions are shown in dashes. Nucleotide substitution is shown in 
lowercase. The net change in length caused by each indel mutation is to the right of each sequence.
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yielded 20 drug-resistant colonies from the #C2 line, 7 which were transposon-free clones, showing a single band 
at 668 bp indicating biallelic excision (Fig. 3c). Molecular genotypes can be inferred from the different banding 
patterns observed. Sequence analysis showed correct in-frame integration and the presence of the characteristic 
“footprint” TTAA sequence28 at the site of transposase excision (Fig. 3d). Additionally, 9/20 clones showed trans-
poson removal from both alleles with at least one transposon re-integrated. 4/20 clones were heterozygous. In 
addition, 11 ganciclovir-resistant colonies were obtained from the #C15 line, all heterozygous.
Hepatic differentiation of mouse iPSCs. Next, we sought to examine whether Arg1 gene editing resulted 
in functional correction in the repaired cells. Since Arg1 is not expressed to any significant extent in iPSCs, but, 
rather, in highest amounts in hepatocytes, the repaired clones (#C2-10 and #C2-18) and parental non-edited 
cells were subjected to hepatic differentiation using a stepwise protocol, which consists of definitive endoderm 
induction, hepatic specification, hepatoblast formation and hepatocyte maturation (Fig. 4a). At the end of this 
25-day differentiation protocol, iPSC-derived hepatocyte-like cells (named iHLCs hereafter) exhibited charac-
teristic hepatocyte morphology such as cobblestone appearance, distinctive round nuclei and well-demarcated 
cell-cell borders with glycogen storage function confirmed by Periodic acid-Schiff (PAS) staining (Fig. 4b). 
RT-PCR (Fig. 4c) and immunohistochemical (Fig. 4d) analysis showed expression of the hepatic marker albu-
min (Alb), as well as alpha-fetoprotein (Afp) in iHLCs but only the former in mature hepatocytes isolated from 
C57BL/6 mice indicating that the iHLCs retain an immature hepatocyte phenotype. A faint band indicating weak 
expression of Arg1 in iHLCs, compared to WT hepatocytes was present. The level of urea production was higher 
in both repaired iHLC lines compared to their non-repaired counterpart; however, the level was still considerably 
low compared to WT hepatocytes (Fig. 4e). The minimal ureagenesis observed in the Arg1Δ hepatocytes is likely 
residual expression resulting from incomplete tamoxifen-mediated removal of exons 7 and 8. Nevertheless, our 
observations are in accordance with a previous report that showed consistent expression of Afp accompanied by 
Figure 3. Reincorporation of Arg1 exons 7 and 8 via homology-directed repair. (a) The experimental strategy 
for precise genome modification using CRISPR/Cas9 and piggyBac transposon methodology. Arrows indicate 
primers for PCR-based screening to confirm the selected clones. The remnant LoxP left from the initial Cre-
excision of exons 7 and 8 would be removed upon targeting vector integration. PBx, piggyBac transposase; T2A, 
viral sequence for ribosomal skipping; Puro, puromycin; ITR, inverted terminal repeat; TK, thymidine kinase. 
(b) Representative gel images of puromycin-resistant iPSC colonies screened for correctly targeted clones. Each 
homology arm was amplified independently by PCR. Amplicon sizes of the left and right arm were 1530 and 
1660 bp, respectively, while random integration should yield a product of ≈300 bp. (c) PCR-based genotyping 
of alleles after piggyBac excision. Upper panel shows primer combination to uniquely identify different alleles. 
Lower panel shows a representative gel of different banding patterns and corresponding genotypes. Amplicon 
sizes of the repaired and targeted alleles were 668 bp and 530 bp, respectively. (d) Footprint analysis by 
sequencing. Sequences in transposon-free repair clones indicating the exact repair after transposon excision. 
TTAA target sites are boxed.
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Figure 4. Generation of hepatocyte-like cells from repaired mouse iPSCs. (a) Schematic diagram showing 
the stepwise hepatic differentiation protocol. (b) Representative phase contrast images showing sequential 
morphological changes in iPSCs at different stages of differentiation (10x magnification). The cells are positive 
for PAS staining at day 25 after the start of the differentiation procedure. (c) RT-PCR gene expression of iHLCs 
for the hepatocyte markers alpha-fetoprotein (Afp), albumin and Arg1. Expression of genes was normalized to 
β-actin. (d) Representative immunostaining images from two independent batches of hepatic differentiation 
showing the expression profile. (e) Functional characterization of iHLCs. After 24 h of culture, supernatants 
were collected for urea production assay. Values were normalized by the number of cells seeded. Values are 
mean ± SD for n = 3 − 4. (f) qPCR expression analysis of the five urea cycle enzymes. The Ct values of all 
genes were normalized to the Ct values of 18S rRNA. The y-axis represents the fold-change of gene expression 
compared with undifferentiated iPSCs. Values are mean ± SD for n = 3. Statistical significance between groups 
was determined by Student’s t-test (*P < 0.05).
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low Arg1 expression and urea synthesis at the final stage of differentiation relative to primary hepatocytes29. To 
evaluate the expression of other urea cycle enzymes, we performed quantitative real-time PCR (qRT-PCR) and 
observed scarce expression of the five main ureagenic enzymes, providing further evidence of incomplete matura-
tion (Fig. 4f). Although repaired iHLCs showed significant higher Arg1 expression when compared to their iPSC 
and non-repaired counterparts, the level is still distinctly lower than in normal adult hepatocytes. Additionally, 
our strategy was designed to distinguish endogenous Arg1 expression from gene edited Arg1 repair and to dis-
criminate signal above cellular autofluorescence by incorporation of a monomeric form of RFP30 fused to the 
carboxy terminus of the enzyme. Previously, we had demonstrated that Arg1 is fully functional with an eGFP 
tag placed in the same location11, 12. However, fluorescent imaging of the gene-edited iHLCs did not demonstrate 
red fluorescence but only very weak green fluorescence (Fig. 4d). These data suggested that either the cells were 
not mature enough for high-level Arg1 expression by the chosen differentiation protocol29 and/or that there were 
problems with maturation of the RFP fluorophore (see Discussion).
Differentiation of mouse iPSCs to macrophages. Given that iHLCs did not show the intended 
result with the fluorescent fusion protein, we opted to differentiate the repaired iPSCs to another cell type that 
strongly exhibits Arg1 expression in mice, namely macrophages of the M2 phenotype31. Macrophages derived 
from both repaired and non-edited iPSC lines analyzed at day 20 of differentiation showed similar morphol-
ogy (bi-/multi-polar with round nucleus and abundant foamy cytoplasm when stained with Wright-Giemsa) 
to bone marrow-derived and peritoneal macrophages (Fig. 5a). RT-PCR analysis revealed an M2 phenotype of 
iPSC-derived macrophages (named iPSC-MΦ hereafter) upon stimulation of IL-4 and IL-10 with evidence for 
F4/80, Fizz1, Ym1 and no iNOS expression, with none of these markers present in iPSCs (Fig. 5b). Induction of 
arginase-1 was also observed at both the protein (Fig. 5c) and mRNA (Fig. 5d) levels. Importantly, macrophages 
derived from repaired iPSC lines, but not non-repaired cells, were able to express Arg1-RFP by fluorescence anal-
ysis (Fig. 5c) and by RT-PCR using primers within Arg1 and RFP domains (Fig. 5d). Gratifyingly, the expression 
of Arg1-RFP fusion was further upregulated upon sodium butyrate treatment (Fig. 5c,d). Therefore, precision 
editing of Arg1∆ alleles with functional correction has occurred in differentiated macrophage populations, indi-
cating that the overall strategy was successful.
Discussion
The focus of this work relates to basic investigations into developing a gene repair strategy for a rare genetic dis-
order such as Arg1 deficiency, so as to halt progression of the disease. In this study, PMEFs obtained from our 
Figure 5. Characterization of iPSC-derived macrophages by assessing mRNA expression of macrophage 
phenotypic markers. (a) Phase contrast (upper panel) and cytocentrifuge preparations of macrophages for 
Wright–Giemsa staining (lower panels). The cells appear purplish and granular. 20x magnification. (b) RT-
PCR analysis of macrophage marker genes in macrophages. Differentiated macrophages demonstrated M2-like 
characteristics. Expression of genes was normalized to β-actin. (c) RFP signal observed in the repaired iPSC-
derived macrophages. (d) mRNA expression levels of Arg1-RFP in macrophages after treatment with IL-4, IL-
10, sodium butyrate (NaB) as assessed by RT-PCR.
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inducible Arg1-deficient mouse model were reprogrammed into iPSCs as a proof-of-concept system to exploit 
CRISPR/Cas9-mediated gene editing. The Arg1-deficient iPSCs exhibited typical embryonic stem cell-like char-
acteristics and possess differentiation ability into three germ layers. Here, we used an all-in-one vector system 
expressing Cas9 and gRNA for our gene targeting approach. The functionality of the CRISPR/Cas9 system was 
validated using plasmid-mediated electroporation of iPSCs. Our results showed that this gene editing tool could 
induce precise sequence alterations within a defined locus of the Arg1 gene. Sequence repair was mediated by 
a targeting vector carrying exons 7 and 8 cDNA-RFP fusion construct and selection cassette. We showed that 
a combination of CRISPR/Cas9 and piggyBac technology can achieve biallelic repair of multi-exon deletion in 
the Arg1 gene without leaving any residual ectopic sequences at the site of correction. The positive-negative drug 
selection-based enrichment strategy enables efficient isolation of multiple correctly targeted and transgene-free 
repaired iPSCs.
For functional studies, the repaired iPSCs were first differentiated into hepatocyte-like cells to assess the resto-
ration of Arg1 gene expression. We successfully generated iHLCs that not only express hepatic markers, but also 
exhibited some normal hepatic functions including glycogen storage and metabolic capabilities, albeit weak, such 
as urea production. Unfortunately, the differentiated iHLCs did not show evidence of RFP fluorophore expression 
from the fusion protein. In our targeting vector, the RFP was designed to fuse immediately downstream of exon 8 
to aid live-cell imaging. RFP expression of the fusion protein should be controlled and driven by the endogenous 
promoter of Arg1, thereby preventing possible overexpression-induced artefacts. In this regard, it is likely that the 
iHLCs were not fully mature in culture to the stage where the fusion protein could be expressed abundantly. This 
postulate was supported by the expression profile indicating that the iHLCs exhibited an immature phenotype 
(persistent expression of Afp and considerably low expression of the urea cycle enzymes) with minimal urea pro-
duction compared to primary adult mouse hepatocytes (Fig. 4). To have a clearer assessment of the various exper-
imental parameters relating to cell maturation status and fluorescent fusion expression, we turned to another cell 
type known to express Arg1 i.e murine macrophages of the M2 phenotype31. Thus, iPSCs were differentiated into 
macrophages and attained an appropriate degree of functional maturity, confirmed by the expression of F4/80, a 
marker preferentially expressed by mature macrophages32. Interestingly, we observed specific red fluorescent sig-
nal in the repaired iPSC-MΦ, which would indicate complete chromophore maturation. Undoubtedly, fluorescent 
fusion protein expression is likely to vary according to the cell type and degree of maturation.
There are several stages leading to the formation of an optically active chromophore within fluorescent pro-
teins that must occur in a correct sequential manner. Problems can arise at each of the different steps involved, 
including translation, protein folding and maturation, oligomerization, photobleaching and degradation, with 
the time course of chromophore formation and protein degradation rates often more difficult to ascertain exper-
imentally33. In general, fluorescent brightness is determined by a number of parameters, including cellular envi-
ronment, expressing cell type, protein expression level and fusion protein partner34, 35. Previous studies have 
shown that fluorescence proteins mature at different rates depending on the type of cell in which they are being 
expressed36. Another explanation for the fusion protein that failed to express correctly in iHLCs may be due to 
chromosomal modification of histones. Indeed, addition of sodium butyrate to the culture medium enhanced the 
overall Arg1-RFP mRNA expression and fluorescence brightness at least in iPSC-MΦ. Given the role of butyrate 
in the modulation of genome expression by altering chromatin structure37, this might help in explaining the 
differentia1 effects on the efficiency of chromophore maturation in the cells. Whether this individual response to 
butyrate, a histone deacetylase inhibitor (HDACi)38, is related to histone modification normally occurring in this 
cell type is unknown. Previous investigations have demonstrated increased production of mature cystic fibrosis 
transmembrane conductance regulator (CFTR) upon butyrate stimulation39, 40. The mechanism is still not fully 
elucidated but is likely to involve the modulation of protein folding.
After we submitted this manuscript, Lee et al.41 reported a CRISPR/Cas9-based strategy utilizing exon 1 of 
the hypoxanthine-guanine phosphoribosyltransferase (HPRT) locus to genetically modify and restore argin-
ase activity using hyperargininemic patient-derived cells. In line with our current study, their differentiated 
hepatocyte-like cells co-express Afp and Alb, indicating an immature phenotype as opposed to adult hepatocytes, 
which is also typically found in many differentiation cultures of mouse and human cells to date. The differences 
in arginase expression and urea production level in our differentiated iHLCs vs their system may be explained by 
the chosen HPRT knock-in locus, as well as the hepatic differentiation protocols used. Although they observed 
a high arginase RNA level and urea production in their corrected undifferentiated hiPSCs, likely due to the 
ubiquitously expressed HPRT gene, there was a significant decline in both ARG1 expression and functionality 
post-differentiation. The decrease is likely a consequence of their use of the elongation factor 1α (Ef1α) promoter 
in the targeting construct, which has been shown to decline in activity post-differentiation42, raising a concern 
about a potential further reduction in ARG1 expression and functionality after cellular transplantation. In con-
trast, our study took advantage of the piggyBac technology by employing a “pop in and out” repair strategy for the 
generation of seamlessly corrected cells under the influence of the endogenous Arg1 promoter in the context of 
its native chromatin landscape.
Taken together, our work provides a proof-of-concept rationale for seamless gene editing of multi-exon dele-
tion in Arg1 using CRISPR/Cas9 in conjunction with piggyBac transposon technology. Moreover, we also provide 
important information about how fusion proteins may function differentially in different cell types. While we 
have successfully repaired Arg1 at the molecular genetic level, our current challenge is to differentiate iPSCs 
into mature hepatocytes at a comparable level to that of adult hepatocytes to verify functional correction. Our 
ongoing efforts include refining our current hepatic differentiation protocol, in particular the final step of dif-
ferentiation to acquire a more mature phenotype. In vivo transplantations of both human and mouse immature 
iHLCs promote further maturation and long-term repopulation of hepatocytes29, 43. Thus, it is possible that the 
transplantation of gene-corrected iHLCs into our mouse model could enhance functional maturation. In addi-
tion, three-dimensional cultures or co-culture with non-parenchymal supportive cells before transplantation 
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may be required to generate functional hepatocytes in vitro that can efficiently engraft into the mouse liver. Our 
initial studies using wild-type hepatocyte transplantation into inducible Arg1-deficient mice has not yet rescued 
animals from the lethal consequences of the disorder12. Successful gene editing and phenotypic corrections with 
gene-edited iPSC-derived cells still has obstacles to overcome before becoming a valuable tool to facilitate the 
development of liver-targeted cell therapies for urea cycle disorders.
Methods
Mice and cell source. The inducible Arg1-deficient mouse strain (herein referred to as Arg1-Cre mice) 
was derived from parental strains Arg1flox (JAX strain 008817, C57BL/6-Arg1tm1Pmu/J) and CreERT2 (JAX strain 
008463, B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J) and bred in-house as previously described4. All procedures were 
reviewed and approved by the Queen’s University Animal Care Committee (approval #Funk-2011-048-R1-A4) 
and conformed to the Guidelines of the Canadian Council on Animal Care. Primary mouse embryonic fibroblasts 
(PMEFs) were isolated from embryos of Arg1-Cre mating pairs 13.5 days post-coitum. Briefly, embryos were 
dissected and the head and the internal organs were removed. The remaining tissue was minced and digested 
overnight with 0.25% trypsin-EDTA (Hyclone) at 4 °C, followed by a 30 min incubation at 37 °C the next day 
to ensure complete tissue digestion. The obtained cells were seeded into gelatin-coated flasks and cultured in 
PMEF medium [high glucose Dulbecco’s modified Eagle’s medium (DMEM), 15% fetal bovine serum (FBS, 
Hyclone), 1% penicillin/streptomycin (Sigma)]. On day 1 and day 3 after seeding, PMEFs were treated with 
0.5 µM 4-hydroxy-tamoxifen (OHT) (Sigma) to induce the deletion of exons 7 and 8 of Arg1 (herein referred to 
as Arg1Δ PMEFs). PCR genotyping was carried out after day 5 of seeding to confirm Cre-excision using PCR with 
primer sets as follows: F1 5′-TGCGAGTTCATGACTAAGGTT-3′, R1 5′-AAAGCTCAGGTGAATCGG-3′ and 
R2 5′-GCACTGTCTAAGCCCGAGAGTATC-3′4.
To prepare feeder layers for culture of iPSCs, wildtype PMEFs were generated from individual mouse 
embryos (C57BL/6 background) and inactivated with 10 µg/ml of mitomycin C (Sigma) at passages 3–5 (P3-5). 
Puromycin-resistant, mitotically-inactivated PMEFs (iPMEFs) for drug selection experiments were a kind gift of 
Dr. Peter Greer (Queen’s University).
Generation and characterization of Arg1Δ mouse iPSCs. Arg1Δ mouse iPSCs were generated from 
Arg1Δ PMEFs using a polycystronic lentiviral construct expressing the canonical reprogramming factors Oct4, 
Klf4, Sox2 and c-Myc25 (STEMCCA Cre-Excisable Constitutive Polycistronic Lentivirus Reprogramming Kit, 
Millipore). All cell cultures were maintained at 37 °C/5% CO2. 3 × 104 PMEFs (≤P3) were plated on a 6-well plate 
and cultured with PMEF medium supplemented with 5 µg/mL Polybrene (Millipore). The cells were infected 
with a multiplicity of infection (MOI) of 30 and the PMEF medium was refreshed every other day. Eight days 
after initiation of viral transduction, the cells were switched to mES medium [Knockout DMEM (Gibco), 15% 
ES-qualified FBS (Hyclone), 5% knockout serum replacement (KOSR, Gibco), 1% GlutaMax (Gibco), 1% peni-
cillin/streptomycin, 0.1% β-mercaptoethanol (Gibco), 1,000 U/ml leukemia inhibitory factor (LIF, Gibco)] and 
refreshed every other day. Colonies were visible on day 14 and picked 4 days later. The colonies with good mor-
phology were manually excised and expanded to 24-well plates containing iPMEFs for derivation of individual 
iPSC lines.
Alkaline Phosphatase Live Stain (Life Technologies) was used to check for pluripotency of the reprogrammed 
mouse iPSCs. For formation of embryoid bodies, iPSCs were cultured in ultra-low attachment dishes (Nunclon 
Sphera). For teratoma formation assay, 2 × 106 undifferentiated mouse iPSCs were injected into the testicular 
capsules of NOD/SCID mice and grown for 8 weeks prior to sacrifice. Surgically-removed teratomas were fixed in 
4% paraformaldehyde and embedded in paraffin. Sections were stained with hematoxylin and eosin for histologic 
evaluation of the three germ layers.
Design and construction of CRISPR/Cas9 plasmids. The pX330 plasmid was obtained from Addgene 
(plasmid #42230)20. We used the online CRISPR Design Tool of the Zhang lab (http://crispr.mit.edu/) to identify 
suitable target sites in intron 6 upstream of the remnant LoxP site and assess the potential occurrence of off-target 
regions. To ensure targeting specificity, one unique target site with no homology elsewhere in the mouse genome 
was chosen. The Arg1 gRNA target sequence, 5′-GCGCTGACAGGAATGTCAGG(AGG)-3′ was cloned into the 
BbsI site of the pX330 vector as described by Ran et al.21. The last three nucleotides (AGG) at the 5′-end is the 
PAM motif. The sequence of the Cas9:gRNA expression vector was confirmed by sequencing prior to experimen-
tal use.
Functional evaluation of targeted DNA cleavage by Cas9:gRNA. Arg1Δ iPSCs (3 × 106) were 
electroporated with 15 µg Cas9:gRNA plasmid DNA to induce double-stranded breaks (Bio-Rad Gene Pulser 
System: 250 V, 500 μF, 0.4 cm cuvettes). Genomic DNA from the electroporated cells was isolated two days later. 
The genomic region surrounding the gRNA target site was amplified with a high-fidelity polymerase (Phusion, 
NEB). Purified PCR products were subjected to a re-annealing process using a step gradient (95–25 °C over 
30 min) to enable heteroduplex formation. For mismatch cleavage assays44, the annealed products were treated 
with Surveyor nuclease (Transgenomics) and resultant cleavage products were analyzed in 8% Tris-borate-EDTA 
polyacrylamide gels. The indel efficiency was quantified based on the relative band intensities measured using 
Quantity One Software (Bio-Rad). The indel percentage was calculated using the following formula: 100 × 
(1 − (1 − (b + c)/(a + b + c))1/2), wherein a is the intact band, b and c represent the Surveyor nuclease digestion 
products. For detection of targeted genome modification, PCR amplicons were subcloned into pCR 2.1-TOPO 
TA vector (Invitrogen) and individual colonies were subjected to sequence analysis.
A custom-designed repair targeting vector with Arg1 homology arms, which consists of exons 7 and 8 
cDNA fused to the coding sequence of monomeric RFP, a hybrid PGK-EM7 promoter, a positive-negative drug 
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resistance cassette carrying a puromycin-thymidine kinase resistance gene, a self-cleaving 2A peptide (T2A), all 
flanked by the piggyBac transposon inverted terminal repeats (ITR) (Transposagen, Lexington, KY) was intro-
duced into the cells together with the Cas9:gRNA plasmid to initiate HDR. The targeting vector was linearized 
with NotI prior to electroporation. L-755,507 (5 µM, Tocris BioScience) was also added to the cells to increase the 
efficiency of donor incorporation27. Puromycin treatment (1 µg/ml) was initiated four days after electroporation 
to identify cells that successfully integrated the targeting vector. The resulting colonies were picked on day 14 
and maintained on puromycin-resistant iPMEFs. PCR genotyping was carried out for both left and right arms 
independently using primers as follows: left arm forward (LA-F) 5′-GTCTGCAGAGATTCGGAAGGTAAC-3′, 
re vers e  (L A-R)  5 ′ -CTGACTAGGGGAGGAGTAGAAGGT-3 ′ ;  r ig ht  ar m for ward  (RA-F) 
5′-GGGACTGACTACCTTAAACCACCT-3′, reverse (RA-R) 5′-GGCTATTGAAGATTTAACATTTGG-3′. 
One of the two PCR primers was designed to anneal outside the region spanned by both homology arms 
to ensure on-target integration. LongAmp Taq DNA polymerase (NEB) was used for amplification of 
both arms. For the detection of random integrations of the targeting vector, the following primers were 
used to amplify both sides of the homology arm-plasmid junction individually: left arm forward (LRI-F) 
5′-CTGCAAGGCGATTAAGTTGGGTAACG-3′, reverse (LRI-R) 5′-CACGATGTCTTTGGCAGATATGCAGG
-3′ ;  right arm forward (RRI-F) 5′-CCGTCAAGACTTTTCACATGCAGTC-3′ ,  reverse (RRI-R) 
5′-GCTCGTATGTTGTGTGGAATTGTGAG-3′. The selection cassette was removed by introducing piggyBac 
transposase (PBx) (Transposagen) into the puromycin-resistant cells. Four days after piggyBac excision, ganciclo-
vir selection (2 µM, Cayman Chemical) was carried out to eliminate the cells that have residual vector expression. 
After a 2-week selection period, colonies were picked and expanded on gelatin-coated dishes without feeder 
cells. Genomic DNA was extracted and subjected to PCR-based screening of transposon-excised clones using 
primers as follows: PBx-F 5′-TCACAGGACTTACAGTGATC-3′; PBx-R 5′-CATGAACTCCTTGATGACG-3′ 
and PB3-P2-Forward 5′-GCGACGGATTCGCGCTATTTAGAAA-3′ (transposon-specific primer). PCR 
products resulting from the removal of the selection cassette were sequenced to confirm the presence of 
the TTAA sequence at the excised site22 and the intended genetic modification. For detection of transposon 
re-integration, the following primers were used: PB-F 5′-CTGCTGCAACTTACCTCCGGGATG-3′ and PB-R 
5′-CCCCCAGAATAGAATGACAC-3′.
Differentiation of iPSCs into hepatocyte-like cells in vitro. To confirm functional correction, the 
corrected cells adapted to feeder-free culture conditions were differentiated into hepatocyte-like cells (HLCs) 
using a modified stepwise protocol as previously described29. Mouse iPSCs were trypsinized into single cell sus-
pensions and resuspended in advanced RPMI containing 10% FBS, 100 ng/ml activin A (R&D Systems) and 
50 ng/ml Wnt3a (R&D Systems). One million cells per well were seeded into 12-well plates coated with 2% 
Matrigel (BD Biosciences) and incubated at 37 °C/5% CO2 for direct definitive endoderm (DE) induction with-
out first undergoing embryoid body formation. FBS was reduced to 0.2% on the following day until day 5. On day 
6–10, the medium was replaced with hepatic commitment medium [advanced RPMI, 2% FBS, 50 ng/ml BMP4 
(PeproTech), 20 ng/ml FGF-2 (PeproTech). On day 11–15, the medium was replaced with advanced RPMI con-
taining 2% FBS and 20 ng/ml HGF (PeproTech) to promote the expansion of early hepatic progenitor cells. To 
induce hepatocyte maturation, cells were cultured in advanced RPMI supplemented with 2% FBS, 20 ng/ml HGF, 
20 ng/ml Oncostatin M (R&D Systems), 50 nM dexamethasone and 1x insulin-transferrin-selenium (Corning) 
for 10 days. The medium was changed every two days. Visualization of RFP signal was performed with a fluores-
cent microscope (Leica, DM IRB, Richmond Hill, ON) fitted with an excitation filter of 545 nm and an emission 
filter of 610 nm for mRFP.
Isolation of primary hepatocytes. Primary hepatocytes were isolated from mice using a modified 
two-step collagenase perfusion system as described previously4.
Periodic Acid Schiff (PAS) staining. Glycogen storage was assessed by Periodic Acid Schiff (PAS) stain-
ing. Cells were fixed 15 min in 4% paraformaldehyde, washed with PBS, permeabilized with 1% Triton-PBS and 
treated with Periodic Acid solution followed by Schiff solution as described by the manufacturer (Sigma Aldrich).
Urea quantification. Urea production was measured as described previously4.
Differentiation of mouse iPSCs into functional macrophages in vitro. Macrophage differentiation 
of iPSCs was performed as previously described45. After 20 days of differentiation, we examined the morpholog-
ical and functional characteristics of these cells. TH2 cytokines, 10 ng/ml IL-4 and 10 ng/ml IL-10 (R&D System) 
were added into the culture for specific induction of arginase-1 in macrophages. Repaired iPSC-macrophages 
were compared to their non-repaired counterparts (parental cells) for evidence of phenotypic characterization.
Preparation of primary macrophages. Unstimulated peritoneal cells were collected by lavage of 
wild-type adult C57BL/6 mice using ice-cold phosphate-buffered saline (PBS). Recovered cells were centrifuged, 
resuspended in RPMI 1640 + 10% FBS + 1% penicillin/streptomycin and cultured for 2 h at 37 °C/5% CO2 after 
which non-adherent cells were removed by washing. Purified macrophages were cultured for 24 hours before 
further manipulation.
Bone marrow-derived macrophages (BMMΦs) were obtained from wild-type adult C57BL/6 mice femurs 
using aseptic techniques. Briefly, marrow cores were flushed into sterile tubes using syringes fit with 23G needles 
and filled with flushing media [Iscove’s Modified Dulbecco’s Medium (IMDM), 2% FBS, 1% penicillin/streptomy-
cin, 50 µM α-monothioglycerol (Sigma)]. Isolated cells were washed once in media, then cultured in macrophage 
media [IMDM, 15% FBS, 1% penicillin/streptomycin, 50 µM α-monothioglycerol, 30% L929 cell conditioned 
medium (as a source of macrophage colony stimulating factor to drive bone marrow cells towards a macrophage 
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phenotype)] in 10 cm bacteriological grade Petri dishes. Non-adherent cells were collected at day 4 and replated 
in macrophage media at a density of 6 × 106 cells/well in 6-well plates. On day 7, resultant cultures were either 
treated with 10 ng/mL IL-4 (R&D Systems) and 10 ng/mL IL-10 (R&D Systems) to stimulate M2 conditions31 or 
received media alone (M0 condition). Cells were harvested 24 h post-stimulation for total RNA extractions.
Cytospin centrifugation and staining. Cells were placed on slides by centrifugation at 700 rpm for 5 min 
(CytoSpin 3 Cytocentrifuge, Shandon). Slides were air-dried prior to staining. For morphological analysis, slides 
were stained with modified Wright–Giemsa stain (Sigma-Aldrich) according to the manufacturer’s protocol.
Gene expression analysis. RNA was extracted from cells using GeneJET RNA Purification Kit 
(ThermoFisher) and treated with DNAse I (1 µg/µl, Invitrogen) as per the manufacturer’s instructions. cDNA was 
generated using an iScript cDNA synthesis kit (Bio-Rad). For RT-PCR, primers (Integrated DNA Technologies) 
were designed to span exon-exon boundaries to avoid the amplification of genomic DNA. The primer sequences 
of the genes studied are listed in Table 1. Expression of individual transcripts was normalized to β-actin expres-
sion. Quantitative PCR was performed using a thermal cycler (Applied Biosystems Model 7500) with SYBR Green 
PCR master mix (BioRad). Melting curves were performed on completion of the cycles to ensure absence of non-
specific products. Relative gene expression was calculated using the comparative threshold method (2−ΔΔCT) and 
is presented as fold-change of transcripts for target genes normalized to the expression of housekeeping gene 18S 
rRNA. Gene expression values in undifferentiated iPSCs were set to 1.
Statistical analysis. All experiments were performed at least in triplicates. Results are expressed as 
mean ± standard deviation (SD). Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software, 
San Diego, California, USA). Means were compared using the two-tailed Student’s t-test. P values of < 0.05 were 
considered statistically significant.
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